Tanabe Seiyaku, Maruho Conclude Licensing Agreement for Phosphodiesterase 4 Inhibitor, External Agent for Skin Disease.Tokyo, Japan, June 9, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Tanabe Seiyaku and Maruho have jointly announced that they have entered into a licensing agreement for phosphodiesterase phosphodiesterase /phos·pho·di·es·ter·ase/ (-di-es´ter-as) any of a group of enzymes that catalyze the hydrolytic cleavage of an ester linkage in a phosphoric acid compound containing two such ester linkages. 4 (PDE PDE Pennsylvania Department of Education PDE Plug-In Development Environment PDE Partial Differential Equation PDE Phosphodiesterases PDE Personal Digital Entertainment PDE Pulse Detonation Engine PDE Product Data Exchange PDE Present-Day English 4) inhibitor, a drug candidate for treating skin disease. Under the agreement terms, Maruho receives an exclusive right to develop and sell the agent in Japan. The PDE4 inhibitor, which was discovered by Tanabe Seiyaku, has a property of inhibiting the activity of inflammatory cells. The agent is expected to be used in the treatment of allergic dermatitis such as atopic atopic /atop·ic/ (a-top´ik) (ah-top´ik) 1. ectopic. 2. pertaining to atopy; allergic. atopic 1. displaced; ectopic. 2. pertaining to atopy. and contact dermatitis. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion